Last reviewed · How we verify
SJP-0132
SJP-0132 is a small molecule that targets the SGLT2 receptor.
SJP-0132 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | SJP-0132 |
|---|---|
| Sponsor | Senju Pharmaceutical Co., Ltd. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
SJP-0132 works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and increasing glucose excretion in the urine.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of genital mycotic infections
- Increased risk of urinary tract infections
- Hypotension
Key clinical trials
- Efficacy and Safety of SJP-0132 Eye Drops in Chinese Patients With Dry Eye Disease (PHASE3)
- Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SJP-0132 CI brief — competitive landscape report
- SJP-0132 updates RSS · CI watch RSS
- Senju Pharmaceutical Co., Ltd. portfolio CI